Under the guidance of Professor Kamil Kranc, we are seeking to recruit a Postdoctoral Training Fellow to work on therapeutic targeting of RNA modifications in acute myeloid leukaemia (AML). The successful candidate will investigate strategies to eliminate leukaemic stem cells and play a central role in developing curative treatments for this aggressive disease. Our recent work has demonstrated that inactivation of readers of the m6A mRNA modification represents a promising, non-toxic strategy for targeting leukaemic stem cells in AML (Paris et al., Cell Stem Cell, 2019; Mapperley et al., Journal of Experimental Medicine, 2021; Turner et al., eLife, 2022). Building on these findings, the postholder will explore the impact of disrupting the YTHDF family of m6A readers on AML biology, identify disease subtypes most responsive to this approach, test novel small-molecule inhibitors in vivo, and uncover synthetic lethal interactions and resistance mechanisms to guide rational combination therapies.
About you
The successful candidate must have:
1. PhD in biochemistry, RNA biology, cell biology, molecular biology, stem cell biology, oncology or similar.
2. Excellent verbal and written communication skills. Essential for communicating research, training others and drafting of reports or publications.
3. Significant experience in RNA biology, stem cell biology, and cancer research.
4. An excellent publication record with a track record of research excellence.
Candidates who are nearing completion of their PhD may apply, but confirmation on awarded PhD is required within 6 months of employment.
The ICR has a workforce agreement stating that Postdoctoral Training Fellows can only be employed for up to 7 years as PDTF at the ICR, providing total postdoctoral experience (including previous employment at this level elsewhere) does not exceed 7 years.
For general information on Postdocs at The ICR, more information can be found here.
Department/Directorate Information
The Haemato-Oncology Group specialises in understanding and targeting leukaemic stem cells, which are responsible for AML initiation, disease progression, relapse, and resistance to conventional therapies. Our group focuses on discovering cures for acute myeloid leukaemia with an aim to identify novel therapeutic targets for selective elimination of LSCs, without disrupting normal haematopoiesis.
What we offer
5. A dynamic and supportive research environment
6. Access to state-of-the-art facilities and professional development opportunities
7. Collaboration with leading researchers in the field
8. Competitive salary and pension